NCT05704920
Integrating Artificial Intelligence Into Lung Cancer Screening.
Recruiting · Not Applicable · Centre Hospitalier Universitaire de Nice · registry updated 2026-10-01
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Lung cancer (LC) screening using low-dose chest CT (LDCT) has already proven its efficacy. The mortality reduction associated with LC screening is around 20%, much higher than the reduction in mortality associated with screening for breast, colon or prostate cancers. Implementing lung cancer screening on a large scale faces two main obstacles: 1. The lack of thoracic radiologists and LDCT necessary for the eligible population (between 1.6 and 2.2 million people in France); 2. The high frequency of false positive screenings: in the NLST trial, more than 20% of the subjects screened were found to have at least one nodule of an indeterminate lung nodule (ILN) whereas less than 3% of ILNs are actually LC. The gold standard for determining on the benign or malignant nature of a nodule is definitive histology. Otherwise, the evolution of the nodule on serial thoracic imaging is a good alternative. The period of indeterminacy of a nodule can be as long as 24 months in many cases, which can be a source of prolonged and sometimes unjustified anxiety for screening candidates....
Inclusion
- Age between 50 and 80 years old
- active smoker or ex-smoker who quit smoking less than 15 years ago
- smoking history of at least 20 pack-years
- signature of the informed consent
- affiliation to French social security
Exclusion
- clinical signs suggestive of cancer
- recent chest scan (\<1 year) for another cause
- radiological abnormality requiring follow-up or additional investigations
- health problem significantly limiting life expectancy from the clinician's point of view
- health problem limiting ability or willingness to undergo lung surgery
- Patients with active neoplasia, except basal cell carcinoma of the skin.